Production (Stage)
EyePoint Pharmaceuticals, Inc.
EYPT
$9.03
$0.171.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 109.29% | -17.39% | -30.77% | 4.09% | 52.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 109.29% | -17.39% | -30.77% | 4.09% | 52.08% |
| Cost of Revenue | 90.85% | 131.66% | 60.41% | 78.20% | 114.67% |
| Gross Profit | -79.47% | -583.26% | -511.62% | -161.24% | -187.80% |
| SG&A Expenses | 3.32% | 16.04% | 23.25% | -9.00% | -3.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.85% | 87.04% | 46.19% | 38.15% | 53.93% |
| Operating Income | -46.57% | -176.62% | -127.45% | -51.78% | -54.59% |
| Income Before Tax | -54.33% | -194.73% | -132.80% | -34.49% | -38.37% |
| Income Tax Expenses | -- | 8.43% | -- | -- | -- |
| Earnings from Continuing Operations | -54.33% | -193.63% | -132.80% | -34.49% | -38.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.33% | -193.63% | -132.80% | -34.49% | -38.37% |
| EBIT | -46.57% | -176.62% | -127.45% | -51.78% | -54.59% |
| EBITDA | -46.40% | -175.66% | -126.42% | -51.06% | -53.94% |
| EPS Basic | -17.06% | -91.78% | -63.94% | 5.02% | 1.98% |
| Normalized Basic EPS | -17.06% | -92.54% | -63.91% | -0.92% | 1.98% |
| EPS Diluted | -17.06% | -91.78% | -63.94% | 5.02% | 1.98% |
| Normalized Diluted EPS | -17.06% | -92.54% | -63.91% | -0.92% | 1.98% |
| Average Basic Shares Outstanding | 31.85% | 53.09% | 42.01% | 41.60% | 41.15% |
| Average Diluted Shares Outstanding | 31.85% | 53.09% | 42.01% | 41.60% | 41.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |